Back to the registry
Agent passport

IBM's Quantum AI for Precision Medicine Powered by GNQ Insilico

IBM Consulting · Operations & Productivity

No attestation published

Certification per AWS Marketplace.

Provenance reach3 of 12 layers traced

Evidence tier Source Confirmed · 3 captures on record

User ratingNot rated0 reviews on the listing
Runs onUnknownProfessional service
ProvenanceUnknown33% of the provenance layers this product can disclose
Evidence riskHighSign in to see the basis for this band.

What the publisher says

As described on AWS Marketplace.

<p>IBM Consulting, in partnership with GNQ Insilico, a California-based precision medicine TechBio company, is bringing the GNQ Suite to market — a quantum-enhanced causal AI platform for drug development, clinical trial design, and patient-specific treatment optimization — delivering defensible, mechanistic evidence that regulators, clinicians, and researchers can interrogate.</p>

<p>The platform combines:</p>

Show the rest of the publisher’s description (24 more lines)

<ul>

<li>A curated, evidence-weighted biomedical causal knowledge graph</li>

<li>Multi-layer causal reasoning, moving from predictive modeling (what is likely to happen) to biologically grounded mechanistic reasoning (how and why it happens) to counterfactual exploration (what if a different intervention were made)</li>

<li>Executed through its Quantum Biological Reasoning Model (QBRM)</li>

</ul>

<p>This architecture enables interventional and counterfactual reasoning across a large-scale causal graph. At the core is a living, multimodal Patient 360 model (BioAvatar) that integrates:</p>

<ul>

<li>EHR</li>

<li>Multi-omics</li>

<li>Imaging</li>

<li>Digital pathology</li>

<li>Streaming data</li>

</ul>

<p>Insights are delivered through BioLens, providing explainable and traceable outputs for scientific and regulatory workflows.</p>

<p>Using this causal framework, GNQ enables:</p>

<ul>

<li>Mechanistic adverse event (AE) hypothesis generation with full causal evidence chains and source provenance</li>

<li>Early and low-frequency safety signal detection, improving lead time vs. traditional case accumulation (timing varies by dataset and implementation)</li>

<li>Individual patient risk stratification for toxicity prediction and contraindication profiling</li>

<li>Resistance trajectory forecasting to support proactive therapy optimization and stratified care</li>

<li>In silico trial design and cohort simulation, including eligibility matching to reduce protocol risk</li>

<li>Explainable, audit-ready narratives for regulatory and clinical workflows (e.g., IND/NDA, PSUR/PBRER, DSMB reviews, tumor boards)</li>

</ul>

<p>Built on AWS leveraging AWS HealthOmics, Amazon EKS, AWS Lambda, Amazon ECR, Amazon S3, Amazon DynamoDB, Amazon RDS (PostgreSQL), AWS Secrets Manager, AWS IAM, and Amazon Bedrock (on roadmap).</p>

Highlights

Highlighted by the publisher on AWS Marketplace.

Benefits include: * Fully HIPAA compliant (US), PIPEDA compliant (Canada) with AWS KMS CMK encryption at rest and in transit, and a 7-year CloudTrail audit log retention. * Causal AI (not black box): Interventional + counterfactual reasoning using Pearl’s Causal Ladder over a large-scale biomedical causal graph * Explainable, audit-ready outputs: Evidence-weighted causal relationships with provenance and traceable reasoning paths

* Zero-shot generalization: QBRM can reason about novel targets and combinations without retraining * Precision oncology support: Detect pathway-level changes early and forecast resistance trajectories * In silico trials and trial matching: Cohort simulation and (where supported) automated eligibility inclusion/exclusion matching against active studies * Regulatory and clinical workflow support: Auto-generated explainable narratives for submissions and reviews

* True Patient 360 (BioAvatar): Multimodal integration across EHR, multi-omics * Early safety insight generation: Mechanistic detection of low-frequency risks with improved lead time vs traditional methods (context-dependent) * Quantum-enhanced computation for binding and metabolism predictions * Federated, data-sovereign architecture: Secure, institution-centered deployments with multi-site collaboration

Agent build and provenance

See the full provenance

The layer-by-layer build, the evidence behind each claim, the risk basis and the cross-marketplace links are open to any account. Some rows are disclosed, some the source leaves Unknown; a free account shows you which.

Sources

Marketplace listingaws.amazon.comSource
App certificationaws.amazon.comSource

Publisher resources

1 link
GNQ AI Drug Dev & Patient Carewww.businesswire.comSource

Linked repositories

RepositoriesUnknownUnknown

Unknown means this listing does not publish a repository. It is not a statement that the code is closed, and a linked repository is not a claim that the publisher wrote it: the registry computes that relationship privately and does not publish it.

Pricing
Unknown
Not stated
Delivery
Professional service
Stuart Pyle (Stuart.Pyle@ibm.com) Mayank Thakkar (Mayank.Thakkar@ibm.com)
Open the source listing ↗

Evidence risk is the share of the build you cannot see before you deploy, not a security rating. Sign in to see the layer-by-layer basis for this band.